Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY

Posted on June 15, 2021 by Gastroenterology Journal

VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab. This analysis compared histologic outcomes.

This entry was posted in News. Bookmark the permalink.